Tuesday, September 26, 2023


Biotechnology News Magazine

MP Biomedicals Launches New Line of Well-characterized Antibodies, antigens, & ELISA Kits to Advance SARS-CoV-2 Research

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

MP Biomedicals, LLC has recently expanded its portfolio of COVID-19-related research products to include a wide selection of highly pure SARS-CoV-2 recombinant proteins, monoclonal antibodies specific and potent against a variety of SARS-CoV-2 protein domains, and high-quality ELISA kits to quantify SARS-CoV-2 and the virus-triggered human IgM and IgG antibodies.

The disease COVID-19, caused by SARS-CoV-2 virus infection, continues to impact public health on a global scale. With new variants rapidly emerging, it is critical that scientists have access to the latest research tools. MP Biomedicals’ extensive line of SARS-CoV-2 research products are fully validated to ensure quality and performance to help advance COVID-19 research.

“Our new collection of COVID-19-related research products is another big step towards our goal of providing researchers with innovative, quality solutions,” said Dr. Xiao-wei Wang, Immunology Product Manager, MP Biomedicals. “We will continue to expand our portfolio and offerings to do our part in addressing the current needs of the scientific community.”

To learn more about MP Biomedicals’ COVID-19 research products, please visit www.mpbio.com/sars-cov-2-research.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine